176,401 Shares in Liquidia Corporation $LQDA Acquired by T3 Companies LLC

T3 Companies LLC bought a new position in shares of Liquidia Corporation (NASDAQ:LQDA) in the 4th quarter, HoldingsChannel.com reports. The fund bought 176,401 shares of the company’s stock, valued at approximately $6,084,000. Liquidia comprises about 7.6% of T3 Companies LLC’s holdings, making the stock its 3rd biggest position.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Liquidia in the 4th quarter valued at $25,000. NewEdge Advisors LLC acquired a new stake in shares of Liquidia during the 2nd quarter worth about $25,000. Skandinaviska Enskilda Banken AB publ purchased a new stake in Liquidia in the 3rd quarter valued at about $30,000. FNY Investment Advisers LLC purchased a new stake in Liquidia in the 3rd quarter valued at about $34,000. Finally, Covestor Ltd lifted its position in Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after buying an additional 359 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Price Performance

Liquidia stock opened at $65.25 on Thursday. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. The company has a fifty day simple moving average of $48.50 and a 200-day simple moving average of $40.37. The stock has a market cap of $5.80 billion, a P/E ratio of 466.10 and a beta of 0.58. Liquidia Corporation has a 12-month low of $11.85 and a 12-month high of $66.78.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. The company’s revenue for the quarter was up 4187.1% compared to the same quarter last year. Equities analysts expect that Liquidia Corporation will post 2.97 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on LQDA. Wells Fargo & Company lifted their price target on shares of Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. Wall Street Zen upgraded shares of Liquidia from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 16th. Jefferies Financial Group reaffirmed a “buy” rating and set a $60.00 price objective on shares of Liquidia in a research report on Monday, May 11th. Lifesci Capital upgraded shares of Liquidia to a “strong-buy” rating in a report on Thursday, March 5th. Finally, Needham & Company LLC boosted their target price on Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Three research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Liquidia has an average rating of “Moderate Buy” and a consensus price target of $60.29.

Insiders Place Their Bets

In other news, Director Stephen M. Bloch sold 318,893 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $50.23, for a total transaction of $16,017,995.39. Following the sale, the director owned 1,870,042 shares of the company’s stock, valued at approximately $93,932,209.66. This trade represents a 14.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Raman Singh sold 29,494 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $60.13, for a total value of $1,773,474.22. Following the sale, the director owned 38,755 shares of the company’s stock, valued at approximately $2,330,338.15. The trade was a 43.22% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 1,673,680 shares of company stock worth $85,949,087. 25.60% of the stock is currently owned by company insiders.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).